A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab…

Overview of attention for article published in BMC Cancer, February 2016

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 28,812 followers.

ベバシズマブの投与は化学療法と同日で良いのか？という疑問から出てきたOBELICS試験。FOLFOXの4日前にBev投与。主要評価項目は奏効率。／BMC Cancer https://t.co/ezP9vcgMyU https://t.co/tdQiHMeusO

大腸癌のオキサリプラチン＋カペシタビン併用療法はXELOXと言われたりCapeOXと言われたりするけど、OXXELという呼び方も有るのか（投与期間も微妙にmodifyされている）。／BMC Cancer https://t.co/rzTWrZk76Y

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment… https://t.co/bNMGGlBIiI

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.